Shares of Greenwich LifeSciences (NASDAQ:GLSI) jumped 26% in premarket trading on Wednesday following news that the company’s breast cancer therapy received an important regulatory milestone.
The biotech firm said its GLSI-100 treatment earned “fast track” designation from the U.S. Food and Drug Administration (FDA).
“This designation is designed to accelerate the development and review process for drugs targeting serious conditions with unmet medical needs,” the company noted.
GLSI-100 is currently undergoing late-stage clinical testing for patients with HER2-positive breast cancer who carry the HLA-A02 genotype and have completed standard treatment regimens.
Greenwich LifeSciences stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.